Internal Medicine

Data from the phase 3 LIMMitless show patients received long-term benefit from the biologic, regardless of baseline demographic or disease status.

Peter Lio, MD, explains firsthand how abrocitinib and upadacitinib became the latest options for his most difficult-to-treat patients.

Raj Chovatiya, MD, PhD, reviews the clinical progression of tapinarof and roflumilast cream headed into the 2022 Fall Clinical.

Fifteen out of 17 studies in a systematic review indicated that the HRD number decreased after DME treatment.

The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.

Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.

Primary Care Physicians (PCPs) play a crucial role in endorsing lifestyle counseling and facilitating integrative care for their patients.

An interview with Dr. Vega regarding atrial fibrillation and clinical manifestations for ADPKD.

The approval indicates the subcutaneous loop diuretic for the at-home treatment of congestion in adults with NYHA Class II/III chronic heart failure.

New data suggest transparency regarding drug safety regulatory response has not been consistent in recent years.

"Especially when untreated and in late stages of progression, ILD is well known to impact health related quality of life," according to Dr. Briana DiSilvio. "Chronic dyspnea, cough, and reduced exercise capacity can become disabling."

A real-world comparison of the anti-VEGF agents suggests certain doses are associated with more likelihood of retreatment.

Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.

Our endocrinology month in review spotlights the most popular content from the past month. Our top content from September 2022 includes new guideline recommendations from the ADA/EASD, new data on semaglutide 2.4 mg and tirzepatide, a label update for finerenone, & more!

The novel OX40 inhibitor molecule showed significant benefit for patients in new EADV 2022 data. A lead author discusses its potential.

The daily TYK2 inhibitor agent was associated with improved rates of psoriasis surface improvement versus apremilast in clinical trials.

Young adults with a high cumulative alcohol burden had up to 25% higher risk of incident AF.

Mesalamine use was linked to fewer relapses in the ulcerative colitis or IBD-unclassified cohorts compared to patients with Crohn’s disease.

In this podcast episode, Jorge Plutzky, MD, and Michael Farkouh, MD, speak with University of Maryland's Matthew Weir, MD, about the growing involvement of renal care in modern heart disease patients.

An analysis of national register data from Sweden suggests elevated HbA1c levels were linked to an increase in the likelihood of developing stenosing tenosynovitis, more commonly known as trigger finger, among people with either type 1 or type 2 diabetes.

In the first episode of our monthly series, cardiologists Jorge Plutzky, MD, and Michael Farkouh, MD, interview nephrologist Matthew Weir, MD.

A cross-sectional analysis of a Penn Medicine primary care practice shows which patients may prefer a phone or tablet versus a computer.

The latest indications for the novel selective antibody will make it available as a treatment for pustular psoriasis.

Whole genome sequencing suggests both common and rare variants contribute to early onset drusen maculopathy.

A recent study indicated no evident VTE risk in patients with eczema, despite FDA black box warnings for the drug class.